Interestingly, disruption of PD-1 gene expression in GPC3 CAR-T cells by the CRISPR/Cas9 gene-editing system increased the in vivo activity of CAR-T cells against HCC, improving their infiltration levels in mouse models (87). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.